Metastatic renal cell carcinoma: Relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: An 18F-fluoromisonidazole PET/CT study

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1048-1055

  Hugonnet, Florent ^a   Fournier, Laure ^a   Medioni, Jacques ^a   Smadja, Corinne ^a   Hindié, Elif ^a   Huchet, Virginie ^b   Itti, Emmanuel ^c   Cuenod, Charles André ^a   Chatellier, Gilles ^a   Oudard, Stéphane ^a   Faraggi, Marc ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL TENON   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Fluoromisonidazole; Metastatic renal cell carcinoma; Sunitinib; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; SUNITINIB;

ADRENAL METASTASIS; ADULT; ARTICLE; CANCER GROWTH; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; HYPOXEMIA; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OVERALL SURVIVAL; PANCREAS METASTASIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL HYPOXIA; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; MISONIDAZOLE; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PYRROLES; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960319686     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084517     Document Type: Article

References (24)

1. Kim W, Kaelin WJ. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev. 2003;13:55-60. (Pubitemid 36143928)
2. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol. 2005;77:18-24. (Pubitemid 41503384)
3. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
4. Motzer R, Hutson T, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
5. Motzer R, Hutson T, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124. (Pubitemid 46089672)
6. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
7. Rajendran J, Schwartz D, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441. (Pubitemid 44497258)
8. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
9. Lee S, Scott A. Hypoxia positron emission tomography imaging with 18f- fluoromisonidazole. Semin Nucl Med. 2007;37:451-461. (Pubitemid 47498258)
10. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett. 2005;221:225-235. (Pubitemid 40460409)
11. Kubota K, Tada M, Yamada S, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med. 1999;26:750-757. (Pubitemid 29338663)
12. 18F]-2-fluoro-2'-deoxyglucose): an appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004;180:616-622.
13. Jain R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62. (Pubitemid 40093472)
14. 18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer. 2007;7:113.
15. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(suppl 5):4-9. (Pubitemid 39658340)
16. Hillman G, Singh-Gupta V, Zhang H, et al. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Neoplasia. 2009;11:910-920.
17. Jansen J, Schöder H, Lee N, et al. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and (18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys. 2010;77:1403-1410.
18. 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96:540-546.
19. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296. (Pubitemid 34032623)
20. Hicks R, Rischin D, Fisher R, Binns D, Scott A, Peters L. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging. 2005; 32:1384-1391. (Pubitemid 41746841)
21. 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009;50:1760-1769.
22. Graser A, Becker CR, Reiser MF, Stief C, Staehler M. Volumetry of metastases from renal cell carcinoma: comparison with the RECIST criteria [in German]. Radiologe. 2008;48:850-856.
23. Pradel C, Siauve N, Bruneteau G, et al. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging. 2003;21:845-851. (Pubitemid 37377477)
24. Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol. 2010;21:936-941.